Baader Bank Analysts Give Roche Holding Ltd. (ROG) a CHF 231 Price Target
Roche Holding Ltd. (VTX:ROG) received a CHF 231 price objective from equities researchers at Baader Bank in a report released on Thursday. The firm currently has a “neutral” rating on the healthcare company’s stock.
Other research analysts also recently issued research reports about the stock. Deutsche Bank AG set a CHF 273 price objective on shares of Roche Holding and gave the company a “buy” rating in a research note on Tuesday, June 27th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Roche Holding in a research note on Tuesday, June 27th. Goldman Sachs Group, Inc. (The) set a CHF 335 price objective on shares of Roche Holding and gave the company a “buy” rating in a research note on Tuesday, June 27th. Citigroup Inc. reaffirmed a “buy” rating on shares of Roche Holding in a research note on Wednesday, July 5th. Finally, Morgan Stanley set a CHF 290 price objective on shares of Roche Holding and gave the company a “buy” rating in a research note on Tuesday, July 11th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of CHF 264.75.
Roche Holding (ROG) opened at 240.90 on Thursday. The stock has a market cap of CHK 205.55 billion and a price-to-earnings ratio of 21.39. Roche Holding has a 52 week low of CHK 218.30 and a 52 week high of CHK 273.00. The firm’s 50-day moving average is CHK 245.30 and its 200 day moving average is CHK 251.05.
ILLEGAL ACTIVITY NOTICE: “Baader Bank Analysts Give Roche Holding Ltd. (ROG) a CHF 231 Price Target” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/19/baader-bank-analysts-give-roche-holding-ltd-rog-a-chf-231-price-target.html.
Roche Holding Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Stock Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related stocks with our FREE daily email newsletter.